8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 5, 2018

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	0-26372		82-0429727
(State or other jurisdiction of incorporation)	(Commission File Number)		(IRS Employer Identification No.)
11682 El Camino Real, Suite 300 San Diego, CA		92130
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 8.01 Other Events

On September 5, 2018, Adamis Pharmaceuticals Corporation (the “Company”) made a presentation regarding the Company at the 20^th Annual HC Wainwright Global Investment Conference. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Exhibit Description
99.1	Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADAMIS PHARMACEUTICALS CORPORATION
Dated:  September 6, 2018	By:	/s/ Robert O. Hopkins
	Name:	Robert O. Hopkins
	Title:	Chief Financial Officer

EX-99.1

ADAMIS PHARMACEUTICALS CORPORATION 8-K

Exhibit 99.1

Corporate Presentation September 2018

2

Products and Pipeline • Symject TM - patented, FDA approved injection device ▪ Symjepi TM (epinephrine) Injection 0.3mg • FDA approved for treatment of anaphylaxis • Sandoz – commercial partner in the US ▪ Symjepi (epinephrine) Injection 0.15mg • under FDA review – action date 9/27 ▪ Naloxone injection – for treatment of opioid overdose – goal to file NDA by YE 2018 • Fast dissolving sublingual tablet containing Tadalafil (Cialis®) – goal to file NDA by YE 2018 3

Products and Pipeline • Beclomethasone metered dose inhaler for treatment of asthma and COPD ▪ Cleared by FDA to begin Phase 3 studies in asthmatic patients • Taper TM – enhanced dry powder inhaler device platform ▪ Fluticasone DPI - for treatment of asthma and COPD; expect to continue proof of concept development during 2018 Drug Outsourcing Division • Wholly - owned FDA registered 503B drug outsourcing facility manufactures sterile and nonsterile compounds for patients, animals, physician clinics, hospitals and surgery centers throughout most of the United States 4

5 • Commercial launch of Symjepi in U.S. (1) • FDA action on lower dose Symjepi (2) • Filing of NDA for naloxone injection • Filing of NDA for sublingual tadalafil tablet • Commencement of Phase 3 studies for beclomethasone 1 Timing of launch and commercial strategy at Sandoz’s sole discretion 2 FDA PDUFA date 9/27/18

6 1 Expected FDA action on sNDA by 9/27/18 2 Anticipate pharmacokinetics study will be sufficient to support NDA 3 Phase 3 study expected to commence by YE 2018 4 Expect to continue proof of concept development during 2018 5 Target milestone PRODUCT NAME TYPE POTENTIAL INDICATION PHASE 1 PHASE 2 PHASE 3 NDA APPROVED SYMJEPI TM (epinephrine) Injection 0.3mg Injectable Anaphylaxis SYMJEPI TM (epinephrine) Injection 0.15mg Injectable Anaphylaxis (1) APC-6000 Naloxone Injectable Opioid Overdose (2) By Year End 2018 (5) APC-8000 Tadalafil Sublingual Disintegrating Tablet Erectile Dysfunction (2) By Year End 2018 (5) APC-1000 Beclomethasone HFA Metered Dose Inhaler (MDI) Asthma/COPD (3) APC-4000 Fluticasone Dry Powder Inhaler (DPI) Asthma/COPD (4)

7 Indication - Anaphylaxis Addressable Market - $1.5 billion (1) FDA approved – Launch pending 1 Source: IQVIA (IMS) National Sales Perspective 2 Source: Adamis Human Factors Studies 3 Source: R. Moss, MD, Annals of Allergy, Asthma and Immunology, 120(2018)532 - 547 • First product using patented, FDA - approved injection device • division of Novartis – commercial partner in U.S. • Working closely with Sandoz to prepare for launch • sNDA filed for lower dose (0.15mg) Symjepi; FDA action expected by 9/27/18 • Intended competitive advantage – small, simple and intuitive to use (2)(3) High dose (66 lbs. or more) Low dose (33 - 66 lbs.)

8 Indication – Opioid Overdose Addressable Market - $335 million (1) Next step – New Drug Application filing • Third product candidate using patented, FDA - approved injection device • Active ingredient, naloxone, is a fast - acting opioid antagonist • Drug overdose epidemic – CDC preliminary statistics show more than 72K drug overdose related deaths in 2017 with greater than 40% caused by synthetic opioids like fentanyl (2) • Novel high dose naloxone proposed - current IM dose is 2 mg/ml to treat opioid overdoses • Higher dose because more potent opioids such as fentanyl causing high mortality • Repeat dosing (up to 83%) has been noted in multiple studies (3) 1 Source: IQVIA (IMS) National Sales Perspective 2 Source: CDC – Centers for Disease Control and Prevention 3 Source: Morbidity and Mortality Weekly Report, April 14, 2017

9 • Developing a fast disintegrating sublingual tablet • Active ingredient – tadalafil • Cialis® 2017 net sales of $1.4 billion in U.S. (3) • Cialis patents and exclusivity expire September 2018 (3) • Intended competitive advantage – similar efficacy and quicker systemic absorption 1 Source: IQVIA (IMS) National Sales Perspective 2 For illustration purposes only and may not reflect final product 3 Source: Eli Lilly 2017 SEC Filings Indication – Erectile Dysfunction Addressable Market - $3.5 billion (1) Next step – PK Study / NDA Filing (2)

10 • Inhaled oral steroid for management of asthma and COPD • Active ingredient – beclomethasone • FDA approved to begin Phase 3 trials • Would likely compete with Teva’s QVAR® • QVAR® 2017 net sales of $361 million (3) • QVAR® patents expired July 2015 (4) • Intended competitive advantage – similar efficacy with lower systemic absorption 1 Source: IQVIA (IMS) National Sales Perspective 2 For illustration purposes only and may not reflect final product 3 Source: Teva 2017 SEC Filings 4 Source: FDA Orange Book 11/01/13 Indication – Asthma/COPD Addressable Market - $2.1 billion (1) Next step – Phase III trial (2)

11 • Dry powder inhaler (DPI) acquired from 3M • Unique design stores drug on micro - structured carrier tape for efficient delivery • Aerosolization energy inherent in device • Can be used with single or combination drugs • Potential for multiple products using this platform which could target multiple segments of the respiratory market • Potential to license device for development of novel therapeutics

12 • First product using patented Taper DPI device • Maintenance therapy for treatment of asthma and COPD • Active ingredient – fluticasone • Anticipate continuing proof of concept development during 2018 • Intended competitive advantage: easy to use, similar efficacy with lower systemic absorption 1 Source: IQVIA (IMS) National Sales Perspective Indication – Asthma/COPD Addressable Market - $500 million (1) Next step – Proof of Concept Study

13 • FDA registered 503B facility • FDA and DEA registered • Licensed in 48 states plus DC and Puerto Rico Core Product Areas ▪ Hospital/Acute Care ▪ Veterinary ▪ Pain Management ▪ Family Practice/ Internal Medicine ▪ Orthopedic ▪ Urology • Manufactures sterile and non - sterile prescription medications for patients, animals, physician clinics, hospitals and surgery centers • Targeting to grow net revenue by 30% over 2017

14 • Commercial launch of Symjepi in U.S. (1) • FDA action on lower dose Symjepi (2) • Filing of NDA for naloxone injection • Filing of NDA for sublingual tadalafil tablet • Commencement of Phase 3 studies for beclomethasone 1 Timing of launch and commercial strategy at Sandoz’s sole discretion 2 FDA PDUFA date 9/27/18